Blueprint Medicines (BPMC) Short Interest Ratio & Short Volume → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Free BPMC Stock Alerts $92.29 +1.68 (+1.85%) (As of 04/23/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Blueprint Medicines Short Interest DataCurrent Short Volume4,370,000 sharesPrevious Short Volume5,150,000 sharesChange Vs. Previous Month-15.15%Dollar Volume Sold Short$414.54 millionShort Interest Ratio / Days to Cover5.6Last Record DateMarch 31, 2024Outstanding Shares61,200,000 sharesPercentage of Shares Shorted7.14%Today's Trading Volume788,709 sharesAverage Trading Volume766,782 sharesToday's Volume Vs. Average103% Short Selling Blueprint Medicines ? Sign up to receive the latest short interest report for Blueprint Medicines and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatBPMC Short Interest Over TimeBPMC Days to Cover Over TimeBPMC Percentage of Float Shorted Over Time Ad True Market InsidersExposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 Blueprint Medicines Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/31/20244,370,000 shares $414.54 million -15.2%N/A5.6 $94.86 3/15/20245,150,000 shares $466.08 million +0.2%N/A6.3 $90.50 2/29/20245,140,000 shares $480.69 million +11.0%N/A5.8 $93.52 2/15/20244,630,000 shares $405.45 million +0.7%N/A5.4 $87.57 1/31/20244,600,000 shares $365.84 million +5.3%N/A5.9 $79.53 1/15/20244,370,000 shares $362.40 million +9.0%N/A5 $82.93 Get the Latest News and Ratings for BPMC and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Blueprint Medicines and its competitors with MarketBeat's FREE daily newsletter. 12/31/20234,010,000 shares $369.88 million -4.1%N/A4.6 $92.24 12/15/20234,180,000 shares $367.55 million -4.1%N/A5.1 $87.93 11/30/20234,360,000 shares $303.63 million +4.6%N/A6.2 $69.64 11/15/20234,170,000 shares $265.50 million -6.3%N/A6.6 $63.67 10/31/20234,450,000 shares $261.93 million +1.4%N/A7.4 $58.86 10/15/20234,390,000 shares $214.80 million -1.1%N/A7.2 $48.93 9/30/20234,440,000 shares $222.98 million +6.7%N/A7.4 $50.22 9/15/20234,160,000 shares $210.58 million +1.7%N/A6.8 $50.62 8/31/20234,090,000 shares $203.93 million +4.6%N/A6.2 $49.86 8/15/20233,910,000 shares $201.17 million +2.9%N/A5.4 $51.45 7/31/20233,800,000 shares $250.80 million +6.2%N/A5.2 $66.00 7/15/20233,580,000 shares $206.24 million -7.3%N/A5.6 $57.61 6/30/20233,860,000 shares $243.95 million -2.3%N/A6.2 $63.20 6/15/20233,950,000 shares $240.52 million +7.1%N/A6.6 $60.89 5/31/20233,690,000 shares $208.56 million +3.1%N/A6.3 $56.52 5/15/20233,580,000 shares $197.40 million -5.8%N/A6 $55.14 4/30/20233,800,000 shares $193.99 million -11.8%N/A6.4 $51.05 4/15/20234,310,000 shares $201.97 million +1.7%N/A7.7 $46.86 3/31/20234,240,000 shares $190.76 million -19.4%N/A7.4 $44.99 3/15/20235,260,000 shares $237.54 million -4.9%N/A9.3 $45.16 2/28/20235,530,000 shares $234.31 million +1.8%N/A9.6 $42.37 2/15/20235,430,000 shares $239.08 million +8.4%N/A10 $44.03 1/31/20235,010,000 shares $234.17 million +4.4%8.6%9.6 $46.74 1/15/20234,800,000 shares $229.68 million +3.7%8.2%7.7 $47.85 12/30/20224,630,000 shares $202.84 million +8.4%7.9%6.8 $43.81 12/15/20224,270,000 shares $192.62 million -0.5%7.3%6.2 $45.11 11/30/20224,290,000 shares $205.02 million +1.2%7.4%6.2 $47.79 11/15/20224,240,000 shares $184.99 million +15.9%7.3%5.9 $43.63 10/31/20223,660,000 shares $189.73 million -10.5%6.3%4.2 $51.84 10/15/20224,090,000 shares $212.60 million -6.2%7.1%4.8 $51.98 9/30/20224,360,000 shares $287.28 million -1.1%7.5%5.4 $65.89 9/15/20224,410,000 shares $320.12 million -20.1%7.6%5.2 $72.59 8/31/20225,520,000 shares $404.17 million +17.0%9.6%5.6 $73.22 8/15/20224,720,000 shares $330.16 million -10.4%8.2%4.9 $69.95Exposed: 10 CENT Crypto to Explode April 20th? (Ad)The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 BPMC Short Interest - Frequently Asked Questions What is Blueprint Medicines' current short interest? Short interest is the volume of Blueprint Medicines shares that have been sold short but have not yet been covered or closed out. As of March 31st, traders have sold 4,370,000 shares of BPMC short. Learn More on Blueprint Medicines' current short interest. What is a good short interest ratio for Blueprint Medicines? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. BPMC shares currently have a short interest ratio of 6.0. Learn More on Blueprint Medicines's short interest ratio. Which institutional investors are shorting Blueprint Medicines? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Blueprint Medicines: Goldman Sachs Group Inc., UBS Group AG, BNP Paribas Financial Markets, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Blueprint Medicines' short interest increasing or decreasing? Blueprint Medicines saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 4,370,000 shares, a decrease of 15.1% from the previous total of 5,150,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Blueprint Medicines' short interest compare to its competitors? Here is how the short interest of companies in the sector of "medical" compare to Blueprint Medicines: Apellis Pharmaceuticals, Inc. (8.66%), Ionis Pharmaceuticals, Inc. (7.11%), Organon & Co. (4.28%), Elanco Animal Health Incorporated (2.53%), BridgeBio Pharma, Inc. (10.29%), Cytokinetics, Incorporated (13.33%), Jazz Pharmaceuticals plc (5.41%), Madrigal Pharmaceuticals, Inc. (16.88%), Nuvalent, Inc. (20.22%), Alpine Immune Sciences, Inc. (8.06%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: TC Energy Co. ($4.49 billion), T-Mobile US, Inc. ($3.94 billion), General Motors ($3.34 billion), Charter Communications, Inc. ($3.32 billion), Occidental Petroleum Co. ($3.21 billion), Super Micro Computer, Inc. ($3.13 billion), Coinbase Global, Inc. ($3.08 billion), Moderna, Inc. ($2.28 billion), Tractor Supply ($2.24 billion), and Royal Caribbean Cruises Ltd. ($2.14 billion). View all of the most shorted stocks. What does it mean to sell short Blueprint Medicines stock? Short selling BPMC is an investing strategy that aims to generate trading profit from Blueprint Medicines as its price is falling. BPMC shares are trading up $1.68 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Blueprint Medicines? A short squeeze for Blueprint Medicines occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of BPMC, which in turn drives the price of the stock up even further. How often is Blueprint Medicines' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including BPMC, twice per month. The most recent reporting period available is March, 31 2024. More Short Interest Resources from MarketBeat Related Companies: Apellis Pharmaceuticals Short Interest Data Ionis Pharmaceuticals Short Interest Data Organon & Co. Short Interest Data Elanco Animal Health Short Interest Data BridgeBio Pharma Short Interest Data Cytokinetics Short Interest Data Jazz Pharmaceuticals Short Interest Data Madrigal Pharmaceuticals Short Interest Data Nuvalent Short Interest Data Alpine Immune Sciences Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:BPMC) was last updated on 4/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersHow to camouflage a factory of 53,000 workersStansberry ResearchDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe #1 Crypto for 2024InvestorPlaceMan Who Predicted 2008: “This Will be Worse.”Altimetry